Alpha Tau Medical Ltd ( (DRTS) ) has released its Q3 earnings. Here is a breakdown of the information Alpha Tau Medical Ltd presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alpha Tau Medical Ltd., an Israeli oncology therapeutics company, is focused on developing the Alpha DaRT technology for treating solid tumors using innovative alpha-radiation therapy.
In its third quarter of 2025, Alpha Tau Medical Ltd. reported significant progress in its clinical trials and operational advancements. The company has initiated patient treatments in a U.S. multi-center pilot study for pancreatic cancer and received a radioactive material license for its New Hampshire facility, positioning it for commercial readiness.
Key financial metrics reveal a net loss of $30.5 million for the nine months ending September 30, 2025, compared to a $22.3 million loss in the same period in 2024. Research and development expenses increased to $22.5 million, reflecting heightened clinical activities, while marketing expenses decreased slightly. The company maintains a strong cash position with $75.9 million in cash, cash equivalents, and deposits.
Looking forward, Alpha Tau is targeting several milestones, including the completion of patient recruitment in pivotal U.S. trials and responses from regulatory bodies in Japan. These developments are expected to further the company’s efforts in commercializing its Alpha DaRT technology.
Alpha Tau’s management remains optimistic about the company’s trajectory, emphasizing continued clinical advancements and strategic preparations for commercial operations in the near future.